SAN

77.39

+2.99%↑

ARGX

727.4

+2.16%↑

SHL.DE

+2.58%↑

PHIA

22.81

+3.26%↑

FRE

37.25

+1.92%↑

SAN

77.39

+2.99%↑

ARGX

727.4

+2.16%↑

SHL.DE

+2.58%↑

PHIA

22.81

+3.26%↑

FRE

37.25

+1.92%↑

SAN

77.39

+2.99%↑

ARGX

727.4

+2.16%↑

SHL.DE

+2.58%↑

PHIA

22.81

+3.26%↑

FRE

37.25

+1.92%↑

SAN

77.39

+2.99%↑

ARGX

727.4

+2.16%↑

SHL.DE

+2.58%↑

PHIA

22.81

+3.26%↑

FRE

37.25

+1.92%↑

SAN

77.39

+2.99%↑

ARGX

727.4

+2.16%↑

SHL.DE

+2.58%↑

PHIA

22.81

+3.26%↑

FRE

37.25

+1.92%↑

Home・Aktien・Guerbet

G
Guerbet

Open

10.4 0.19

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.22

Max

10.5

Schlüsselkennzahlen
By Trading Economics
Einkommen	-114M -111M
Verkäufe	11M 399M
KGV Branchendurchschnitt	13.443 49.888
Gewinnspanne	-27.836
Angestellte	2,653
EBITDA	-28M 14M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+22.77% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-24M 132M
Vorheriger Eröffnungskurs	10.21
Vorheriger Schlusskurs	10.4

Guerbet Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Guerbet Prognose

Kursziel

By TipRanks

22.77% Vorteil

12-Monats-Prognose

Durchschnitt 17.09 EUR 22.77%

Hoch 17.093 EUR

Tief 17.093 EUR

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guerbet – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Guerbet – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Guerbet

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France.